Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

{
  "signal_id": "340a7956-c19f-bd92-0d84-78777e2a960e",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-08-26T01:42:27+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "url": "https://www.biospace.com/press-releases/abbott-receives-fda-authorization-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes",
    "title": "Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes - BioSpace",
    "excerpt": "ABBOTT PARK, Ill. , Aug. 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people living with diabetes of rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency, a serious health complication for people with diabetes. Libre Duo 10 Day delivers real-time visibility into glucose levels needed for daily diabetes management while also monitoring rising ketones in the background, avoiding additional mental or physical burden for people with diabetes. Abbott plans to launch Libre Duo 10 Day in the United States later this year. First-of-its-kind technology Libre Duo 10 Day received De Novo authorization after securing breakthrough device designation from the FDA through a program designed to help people gain faster access to innovative medical technologies. It's the first system to meet the FDA's integrated continuous glucose monitoring (iCGM) standard and the new integrated continuous glucose and ketone monitoring (iCGK) standard, which establishes a benchmark for continuous ketone monitoring in the United States. Monitoring ketones in the background DKA is the most common hyperglycemic emergency for people living with diabetes, 1,2 and...",
    "product": "Libre Duo 10 Day",
    "summary": "Abbott announced that the U.S. Food and Drug Administration (FDA) has authorized its Libre Duo 10 Day system, the world's first dual glucose-ketone sensing technology, which it plans to launch in the United States later in 2026.",
    "location": "United States",
    "planning": true,
    "image_url": "https://static.biospace.com/dims4/default/d32393a/2147483647/strip/true/crop/1120x630+40+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fcc%2F88%2Fa9fddaf440db946b77e1d45d2e26%2Fbiospace-5.png",
    "confidence": 1,
    "product_data": {
      "name": "Libre Duo 10 Day",
      "full_text": "Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology",
      "fuzzy_match": false,
      "release_type": "system"
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-08-26T01:42:27Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-25",
    "article_sentence": "Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology."
  }
}

curl https://signals.autobound.ai/v1/signals/340a7956-c19f-bd92-0d84-78777e2a960e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","limit":20}'